Browsing: GLP1

Canadian employers are broadening access to glucagon-like peptide-1 (GLP-1) drugs for weight loss, with the share offering that coverage rising to 37 percent in 2026 from 17 percent in 2024. 

To support patients facing supply or financial hurdles, Noom has launched a free iteration of its GLP-1 Companion software, eliminating the previous subscription barrier. The application, which helps manage GI side effects, mitigate muscle mass depletion, and track baseline behavior, is now accessible to all individuals on weight-loss medications, independent of their primary provider

Some people develop long COVID after a SARS-CoV-2 infection, and people with type 2 diabetes have an especially high risk

As more adults compare convenient and potentially more affordable GLP-1 care in 2026, this Zevay review explores advertised semaglutide and tirzepatide pricing, online provider evaluation, pharmacy fulfillment, eligibility requirements, and the practical details buyers should understand before enrolling

The scope of use for the anti-obesity drug Wegovy (active ingredient semaglutide) is expanding beyond weight loss to include the prevention of cardiovascular disease, improvement of fatty liver, mental health benefits, and enhanced fertility. 

Losing weight with GLP-1 drugs is only half the battle. Keeping it off long term has proved even harder

Over the past few years, the conversation around GLP-1 receptor agonists has been dominated by extremes: dramatic weight loss in clinical trials, before-and-after transformations on social media, and a public discourse that has oscillated between miracle and backlash. Patients are now asking pointed and more practical questions. Do I need the full dose if I only…

1 receptor agonists may reduce obesity related cancer risk through metabolic and direct cellular mechanisms, according to new evidence

The global GLP-1 market revenue surpassed USD 58.40 billion in 2025 and is predicted to attain around USD 212.73 billion by 2035, growing at a CAGR of 13.80%. The market is driven by the increasing prevalence of obesity and type 2 diabetes throughout the world, the effectiveness of GLP-1 agonists in terms of significant weight…

GLP-1 Analogues Market to Reach US$ 299.08 Billion by 2033 as Press release 1 Analogues Market to Reach US$ 299.08 Billion by 2033 as Obesity, Diabetes and Chronic Weight Management Reshape Metabolic Care 07-09-2026 06:28 PM CET | Business, Economy, Finances, Banking & InsurancePress release from: DataM intelligence 4 Market Research LLP The global glucagon-like…